Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

48 trials with published results (19%)

Research Maturity

199 completed trials (81% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

8.5%

21 terminated out of 247 trials

Success Rate

90.5%

+3.9% vs benchmark

Late-Stage Pipeline

5%

12 trials in Phase 3/4

Results Transparency

24%

48 of 199 completed with results

Key Signals

48 with results90% success21 terminated

Data Visualizations

Phase Distribution

230Total
Not Applicable (5)
Early P 1 (1)
P 1 (201)
P 2 (11)
P 3 (2)
P 4 (10)

Trial Status

Completed199
Terminated21
Unknown12
Recruiting8
Withdrawn4
Not Yet Recruiting2

Trial Success Rate

90.5%

Benchmark: 86.5%

Based on 199 completed trials

Clinical Trials (247)

Showing 20 of 20 trials
NCT06911320Phase 1Completed

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT07715175Phase 1Not Yet RecruitingPrimary

The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.

NCT07348237Phase 1Recruiting

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT03896750Phase 1CompletedPrimary

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

NCT03289208Phase 1CompletedPrimary

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

NCT07217886Phase 1CompletedPrimary

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

NCT07551570Phase 1RecruitingPrimary

Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function

NCT06671444Phase 1Completed

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment

NCT07033182Phase 1Completed

Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment

NCT07154901Phase 1CompletedPrimary

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

NCT07559396Phase 1RecruitingPrimary

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

NCT07315360Phase 1RecruitingPrimary

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

NCT06589713Phase 1CompletedPrimary

Effect of Renal Impairment on Enpatoran Pharmacokinetics

NCT07165015Phase 1CompletedPrimary

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

NCT07017933Not ApplicableRecruiting

Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes

NCT06408597Not ApplicableActive Not Recruiting

Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy

NCT07426380Phase 1Recruiting

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

NCT06352411Phase 1Completed

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

NCT06835127CompletedPrimary

Ultra-low Dose Contrast for Endovascular Procedures

NCT07012005Phase 1CompletedPrimary

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Scroll to load more

Research Network

Activity Timeline